These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 26940242

  • 1. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
    Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB, PharmaCog Consortium.
    J Intern Med; 2016 Jun; 279(6):576-91. PubMed ID: 26940242
    [Abstract] [Full Text] [Related]

  • 2. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
    Albani D, Marizzoni M, Ferrari C, Fusco F, Boeri L, Raimondi I, Jovicich J, Babiloni C, Soricelli A, Lizio R, Galluzzi S, Cavaliere L, Didic M, Schönknecht P, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Bocchio L, Salvatore M, Rossini PM, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Forloni G, Frisoni GB, PharmaCog Consortium.
    J Alzheimers Dis; 2019 Jun; 69(1):37-48. PubMed ID: 30149449
    [Abstract] [Full Text] [Related]

  • 3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 4. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB, PharmaCog Consortium.
    J Alzheimers Dis; 2019 Oct; 69(1):49-58. PubMed ID: 30958351
    [Abstract] [Full Text] [Related]

  • 5. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.
    Marizzoni M, Ferrari C, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ribaldi F, Rossini PM, Schönknecht P, Salvatore M, Soricelli A, Hensch T, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB, PharmaCog Consortium.
    J Alzheimers Dis; 2019 Oct; 69(1):3-14. PubMed ID: 29914031
    [Abstract] [Full Text] [Related]

  • 6. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity.
    Jovicich J, Babiloni C, Ferrari C, Marizzoni M, Moretti DV, Del Percio C, Lizio R, Lopez S, Galluzzi S, Albani D, Cavaliere L, Minati L, Didic M, Fiedler U, Forloni G, Hensch T, Molinuevo JL, Bartrés Faz D, Nobili F, Orlandi D, Parnetti L, Farotti L, Costa C, Payoux P, Rossini PM, Marra C, Schönknecht P, Soricelli A, Noce G, Salvatore M, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Frisoniand GB, the PharmaCog Consortium.
    J Alzheimers Dis; 2019 Oct; 69(1):15-35. PubMed ID: 30400088
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage Clin; 2018 Oct; 19():190-201. PubMed ID: 30023169
    [Abstract] [Full Text] [Related]

  • 8. Biomarker positive and negative subjects in the ADNI cohort: clinical characterization.
    Kennedy RE, Schneider LS, Cutter GR, Alzheimer's Disease Neuroimaging Initiative.
    Curr Alzheimer Res; 2012 Dec; 9(10):1135-41. PubMed ID: 22963265
    [Abstract] [Full Text] [Related]

  • 9. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y, Tan L, Wang HF, Liu Y, Hao XK, Tan CC, Jiang T, Liu B, Zhang DQ, Yu JT, Alzheimer’s Disease Neuroimaging Initiative.
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF, Reinvang I, Selnes P, Grambaite R, Fladby T, Hessen E.
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [Abstract] [Full Text] [Related]

  • 11. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
    Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2010 Jul 13; 75(2):143-51. PubMed ID: 20625167
    [Abstract] [Full Text] [Related]

  • 12. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
    Marizzoni M, Ferrari C, Babiloni C, Albani D, Barkhof F, Cavaliere L, Didic M, Forloni G, Fusco F, Galluzzi S, Hensch T, Jovicich J, Marra C, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ranjeva JP, Ribaldi F, Rolandi E, Rossini PM, Salvatore M, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB.
    Neurobiol Aging; 2020 May 13; 89():55-62. PubMed ID: 32029236
    [Abstract] [Full Text] [Related]

  • 13. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
    Schneider LS, Kennedy RE, Cutter GR, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Dement; 2010 Sep 13; 6(5):367-77. PubMed ID: 20813339
    [Abstract] [Full Text] [Related]

  • 14. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA, Pua EP, Zhou J, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2015 Sep 13; 45(1):253-68. PubMed ID: 25524955
    [Abstract] [Full Text] [Related]

  • 15. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.
    J Intern Med; 2014 Apr 13; 275(4):418-27. PubMed ID: 24237038
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F, Pupo G, Giraldo E, Badìa MC, Monllor P, Lloret A, Schininà ME, Giorgi A, Cini C, Tramutola A, Butterfield DA, Viña J, Perluigi M.
    Free Radic Biol Med; 2016 Feb 13; 91():1-9. PubMed ID: 26675344
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.